- Home
- AITR vs CMRX Comparison
AITR vs CMRX Comparison
Compare AITR & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AITR
- CMRX
- Stock Information
- Founded
- AITR 2022
- CMRX 2000
- Country
- AITR United States
- CMRX United States
- Employees
- AITR N/A
- CMRX N/A
- Industry
- AITR
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- AITR
- CMRX Health Care
- Exchange
- AITR Nasdaq
- CMRX Nasdaq
- Market Cap
- AITR 82.6M
- CMRX 77.0M
- IPO Year
- AITR 2023
- CMRX 2013
- Fundamental
- Price
- AITR $10.54
- CMRX $0.93
- Analyst Decision
- AITR
- CMRX Strong Buy
- Analyst Count
- AITR 0
- CMRX 1
- Target Price
- AITR N/A
- CMRX $11.00
- AVG Volume (30 Days)
- AITR 71.3K
- CMRX 119.4K
- Earning Date
- AITR 01-01-0001
- CMRX 11-08-2024
- Dividend Yield
- AITR N/A
- CMRX N/A
- EPS Growth
- AITR N/A
- CMRX N/A
- EPS
- AITR N/A
- CMRX N/A
- Revenue
- AITR N/A
- CMRX $144,000.00
- Revenue This Year
- AITR N/A
- CMRX $3,040.12
- Revenue Next Year
- AITR N/A
- CMRX N/A
- P/E Ratio
- AITR N/A
- CMRX N/A
- Revenue Growth
- AITR N/A
- CMRX N/A
- 52 Week Low
- AITR $10.11
- CMRX $0.75
- 52 Week High
- AITR $10.57
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- AITR 78.43
- CMRX 60.78
- Support Level
- AITR $10.51
- CMRX $0.80
- Resistance Level
- AITR $10.57
- CMRX $0.98
- Average True Range (ATR)
- AITR 0.01
- CMRX 0.05
- MACD
- AITR -0.00
- CMRX 0.01
- Stochastic Oscillator
- AITR 83.33
- CMRX 83.33
About AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares
AI Transportation Acquisition Corp is a blank check company.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.